These observations therefore suggest that the observed synergistic effects on melanoma cell proliferation and tumour growth of BRAF/MEK plus CDK4/6 inhibition occurs independently of the major metabolic pathways linked with response to BRAF and MEK targeted therapies. Here, BRAF is linked to melanoma.